immediately after intervention for ISR. We evaluated yellow color grade (grade 0-3), neointima coverage grade (grade 0-2), and thrombus (presence or absence) at the culprit lesion. The patients were divided into two groups according to the maximum yellow color grade of the lesion (White: grade 0 or 1 vs. Yellow: grade 2 or 3) and their ISR recurrence was examined by angiography at one-year follow-up. Diameter stenosis >50% was defined as ISR. Results: The incidence of ISR recurrence was higher in the patients with yellow ISR lesion than in those with white ISR lesion (67.8% vs. 10.0%, p¼0.018). Thrombus was not detected in both groups. Neointima coverage grade was not different between the groups. Conclusion: The patients with yellow ISR lesion had the higher incidence of ISR recurrence than those with white ISR lesion.
Background: SF was more commonly reported in sirolimus-eluting stent (SES), right coronary artery (RCA), longer duration of implant and longer stent length. However the timing of stent fracture of each coronary is unknown. The purpose of this study is to assess the time point at which SF of each coronary occurs by the multidetector computed tomography (MDCT). Methods: We performed 64-slice MDCT on asymptomatic and event-free 114 patients (156 lesions) who received SES implantation. These lesions are all RCA and left anterior descending artery (LAD) to compare two coronary arteries. We investigated the rate of SF, in-stent restenosis (ISR) and peri-stent aneurysms caused by SF. MDCT definition of SF is complete separation or partial separation of stent struts. The average first CT follow-up period was 24.6months (5-75months). Then we conducted the second MDCT 42.8 months (12-71 months) later after the first MDCT to non-SF 45 patients (48 lesions). Results: SF was identified in 32 lesions of 156 lesions (20.5%) at the first MDCT. In RCA, 14 stent fractures of 39 lesions were observed. Fracture rate was 35.8%. In LAD, 18 stent fractures of 117 lesions were observed. Fracture rate was 15.3%. SF was more observed in RCA than LAD at the first MDCT (P¼0.006). ISR induced by SF was 1 lesion (3.1%), peri-stent aneurysms were 2 lesions (6.2%). At the second MDCT, new SF occurred in 3 lesions of non-SF 48 lesions. The rate of new SF was 6.2%. The coronary of new SF was all LAD and new SF didn't occur at RCA. About these 3 lesions, ISR and peri-stent aneurysm induced by SF were not detected. Conclusion: SF was more observed in RCA than LAD at the first MDCT, however the new SF was identified in only LAD. About LAD, it is possibility to increase the rate of SF in chronic phase. We continue to follow up the patients who received SES implantation. Background: Percutaneous coronary interventions (PCI) to small-diameter vessels remain an important challenge because of increased complications. Methods: Between May 2011 and January 2012, 83 patients with very small coronary vessels (reference vessel diameter <2.5 mm) were submitted to PCI. Biolimus-eluting stent (BES) was deployed at a low pressure with long inflation time. Results: Two cases of distal edge dissection were observed and one of them needed additional stent implantation. Postprocedural TIMI grade 3 flows were achieved in all patients. There were no death, myocardial infarction (MI) and target lesion revascularization (TLR) during the initial hospitalization. The angiographic data is shown in Figure. Average luminal diameters(ALD) in distal segments significantly increased from baseline (1.36AE0.49 mm vs. 1.56AE0.31, p<0.01). At 12 months after procedure, the rate of TLR was 8.0%. There were no cardiac death and MI related to target lesions. Distal ALD tended to increase from initial procedure (1.71AE0.30mm, p¼0.07). Conclusion: BES implantation to very small coronary vessels achieved a high clinical success and luminal diameter distal to stent significantly increased and remained unchanged at 12-month follow-up. Background: Stent thrombosis has been strongly associated with discontinuation of dual antiplatelet therapy. The central point of stent thrombosis seems to be the impaired, or delayed re-endothelialization, and the most important histological and morphometric predictors of late stent thrombosis (LST) were endothelial coverage and the ratio of uncovered to total stent struts after drug-eluting stent (DES) implantation. However, recent controversies regarding the risk of stent thrombosis in patients receiving DES has brought up the issue of the appropriate duration of antiplatelet therapy after percutaneous coronary intervention, and a recent study reported that the use of extended DAPT for a period longer than 12 months in patients who had received DES was not significantly more effective than aspirin monotherapy in reducing the rate of MI or death for cardiac causes. While second generation DES promote more favorable vascular healing comparing to first generation DES, biodegradable polymer containing stents might have a yield in terms of duration of dual antiplatelet therapy (DAPT) than durable polymer stents. We aimed to test whether biolimus-eluting stent (BES) with 6-month DAPT would be non-inferior 12-month clinical and angiographic outcome to Zotarolimus-eluting stent (ZES) with 6-month DAPT. Methods: This is a prospective, randomized, open-label, multicenter trial to compare clinical events and angiographic data between BES and ZES stents. Currently, 621 patients were randomly assigned. The primary end point was a major adverse cardiac events (MACE) at 12 months. Optical coherence tomography (OCT) at 6 month was performed in 30 patients of each group. The primary endpoint was MACE, secondary end points are target lesion failure, in-segment late loss (LL) at 12 months, and neointimal hyperplasia (NIH) and uncovered stent strut (%) by OCT at 6month. Results: Currently, clinical follow-up was available in 325 patients and angiographic follow-up in 311 patients. The primary endpoints were not statistically different between the BES and ZES, including MACE (5.5 vs. 6.4%; p ¼0.76) and stent thrombosis (0.3 vs. 0.3%; p ¼ 0.99). The secondary endpoints also were not significantly different between BES and ZES, including target lesion failure (2.0 vs. 1.6%; p ¼ 0.53), in-segment LL (mm) at 12 months (0.09AE0.37 vs. 0.05AE0.39, p ¼0.61). OCT at 6 month revealed that mean NIH thickness (mm) of BES and ZES were 59.1AE30.3, 54.0AE25.6, respectively (p¼0.49), and uncovered stent strut percentage (%) of BES and ZES were 20.5AE21.8, 17.7AE22.4, respectively (p¼0.63). Conclusion: BES with biodegradable polymer with 6 month DAPT did not increase the risk of MACE, stent thrombosis, target lesion failure, and LL at 12 months comparing with ZES with durable polymer. The 2nd generation DES including BES and ZES are comparably efficacious. Our results need to be confirmed in larger trials, and further follow up data. Results: There were 202 subjects (n¼406 lesions) enrolled. The mean age was 60.1 years (standard deviation [SD], 9.8), 85% (n¼171) of patients were male, and 46% (n¼93) had diabetes. DAPT use was 92% (n¼185/201) at 6 months and 91% (n¼182/ 201) at 1 year. Mean lesion length was 15.3 mm (SD, 6.6) and 61.1% were ACC/AHA class B2/C. The rate of TVF at 1 year was 4.5% (n¼9/202); the rate of TLF was 4.0% (n¼8/202). Cardiac death occurred in 0.5% (n¼1) of patients, TVMI in 2.5% (n¼5), clinically-driven TVR in 1.5% (n¼3), and clinically-driven TLR in 1.5% (n¼3). There were no events of Academic Research Consortium definite or probable stent thrombosis. Conclusion: Use of the R-ZES was safe and effective with a low rate of clinical events and no stent thrombosis events in Asian patients with dual-vessel coronary artery disease.
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Background: The efficacy of drug eluting stent for saphenous vein graft (SVG) is proven, however the difference of the location of the recipient artery remains unclear. In this study, we compared angiographic outcome for SVG, including in-stent restenosis (ISR), stent fracture (SF) or target lesion revascularization (TLR) among recipient native vessel territory (left circumflex artery group versus left ascending and right coronary artery group). Background: In spite of availability of drug-eluting stent (DES), clinical outcome of percutaneous coronary intervention for right coronary ostial lesion (RCAos) is still poor. So we investigated the angiographic and clinical outcome of DES implantation for True RCAos. Methods: This was a single center non-randomized retrospective study. From April 2007 to July 2012, 67 consecutive patients who underwent DES implantation for de novo RCAos were included. RCAos was defined as the lesion being within 3 mm of the ostium. We defined True RCAos as lesion contained just RCA ostium. Subjects were classified into two groups: the patients treated for True RCAos (True group, 35 patients) and for Not true RCAos (Not true group, 32 patients). Endpoint was binary restenosis at 10 months and target lesion revascularization (TLR) at 12 months. Results: True group was older than Not true group. There were no significant differences between two groups in gender, hypertension, hyperlipidemia, diabetes, and hemodialysis. Despite True group had shorter stent length and larger lesion diameter, they had a higher rate of binary restenosis at 10 months (35.5% vs. 10.0%, p<0.05) and TLR at 12 months (28.6% vs. 6.3%, p<0.05) than Not true group. Conclusion: Our data indicates that the outcome of DES implantation for True RCAos is worse than that of DES implantation for Not true RCAos.
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